**Background:** Transgender and gender-diverse youth experience significantly higher rates of suicidal ideation and suicide attempts compared to their cisgender peers. Researchers have investigated whether gender-affirming care – which may include social transition, puberty blockers, and hormone therapy – can improve mental health outcomes and reduce suicide risk in this vulnerable group. Gender-affirming care is intended to alleviate dysphoria by aligning a youth’s body and social role with their gender identity, which in theory could decrease the distress and risk factors that contribute to suicidality.

**Evidence from Research:** A growing body of evidence suggests that access to gender-affirming medical interventions is associated with *lower* rates of depression and suicidality among transgender youth. For example, a 2022 prospective study of 104 transgender and nonbinary adolescents (ages 13–20) found that those who received puberty blockers or gender-affirming hormones over a 12-month period had **73% lower odds of suicidality** (self-harm or suicidal thoughts) compared to those who did not receive these treatments [1]. This study, conducted in a multidisciplinary gender clinic setting, also observed significantly lower odds of moderate-to-severe depression in the treated group, indicating notable mental health benefits [1]. Another large study published in 2022 examined survey data from more than 9,000 transgender and nonbinary youth. It reported that youth <18 years old who *received* gender-affirming hormone therapy had significantly lower likelihood of recent depression and **were about 40% less likely to have attempted suicide in the past year** compared to those who *wanted* hormone therapy but could not access it [2]. In other words, transgender teens who got the treatment they sought were substantially less prone to depression and suicide attempts than their peers who were denied care [2]. These findings underscore a consistent pattern: youth able to undergo gender-affirming treatment tend to report better mental health and reduced suicidal thoughts.

Medical interventions during adolescence that affirm gender identity may also confer long-term protective effects. A 2020 study focused on puberty blockers (gonadotropin-releasing hormone analogues) found that transgender adults who had accessed puberty suppression in their teens had significantly lower odds of lifetime suicidal ideation than those trans adults who wanted puberty blockers but did not receive them in adolescence [3]. Specifically, the odds of ever having suicidal ideation were **70% lower** for those who received puberty suppression, suggesting a lasting positive impact on mental health [3]. Likewise, early clinical follow-up studies support the mental health value of gender-affirming care. In a Dutch longitudinal study, a cohort of 55 transgender youth was tracked from early adolescence (before treatment) into young adulthood after they had received puberty blockers, hormone therapy, and gender-affirming surgeries. The researchers reported that **gender dysphoria was relieved and overall psychological functioning steadily improved** for these individuals, to the point that their well-being and happiness in young adulthood were comparable to peers in the general population [4]. Notably, after completing gender-affirming treatment, participants’ quality of life and satisfaction were as high as (or higher than) those of non-transgender youth, and none of the treated youth exhibited regrets about transition in that study. Such outcomes illustrate how aligning the body with one’s affirmed gender can markedly reduce the distress that drives suicidality.

**Quality of Evidence and Consensus:** The preponderance of peer-reviewed studies supports the view that gender-affirming care is associated with reduced suicide risk in youth, which is why major medical organizations (such as the American Academy of Pediatrics and the American Psychiatric Association) endorse these interventions for eligible transgender youth. It’s important to acknowledge, however, that most available data come from observational studies rather than randomized trials (for practical and ethical reasons). A 2023 narrative review of the literature noted that **the majority of studies do show a reduction in suicidality following gender-affirming treatment**, but it also cautioned that many studies have methodological limitations (e.g. lack of long-term follow-up or control groups) that make it hard to definitively prove causation [5]. In short, while *association* between gender-affirming care and improved mental health is well documented, researchers emphasize the need for more rigorous long-term studies. Future research should control for confounding factors (such as co-occurring mental health conditions and family support) to more conclusively determine the extent of suicide risk reduction attributable to these treatments [5]. 

It’s also worth mentioning that a few analyses have challenged the conclusion that gender-affirming interventions lower youth suicide rates. For example, a 2022 report from a public policy think-tank argued that making puberty blockers and hormones more easily accessible to minors (by reducing requirements for parental consent) did *not* correlate with reduced statewide youth suicide rates – the report controversially claimed it **may even coincide with higher youth suicide rates** in those areas [6]. However, the methodology and conclusions of this report have been widely criticized by experts for drawing causal claims from population-level data without adequately accounting for other factors. In contrast, virtually all *individual-level* clinical studies and surveys indicate that when transgender youth receive the gender-affirming care they desire, their mental health outcomes – including measures of suicidality – improve significantly [2][3][4]. The consistent findings of reduced depression and suicidal ideation in treated youth [1][2][3] align with what clinicians report anecdotally: supporting a young person’s gender identity through appropriate care can be life-saving.

**Conclusion:** Overall, evidence **strongly suggests that gender-affirming care is linked to lower suicide risk among transgender youth**, primarily by easing the extreme distress (gender dysphoria) that contributes to suicidal thoughts. Multiple studies have found substantially lower rates of suicidal ideation and attempts in youth who access puberty blockers and hormone therapies, compared to those who do not receive such care [1][2][3]. Youth who feel supported in their gender identity typically show **improved mental health and well-being**, which is a protective factor against suicide [4]. While ongoing research is needed to continue evaluating long-term outcomes and to strengthen the evidence base [5], the current consensus in the medical community is that gender-affirming care plays a positive role in reducing the extraordinarily high suicide risk faced by transgender and gender-diverse youth [1][2][4]. In practice, providing affirming care – alongside family support and mental health resources – is viewed as an important intervention to help save lives and allow these young people to thrive.

**Sources:**

1. **Tordoff et al., 2022** – *Prospective cohort study in JAMA Network Open.* This study followed 104 transgender and nonbinary youths over 12 months. It found that those who received gender-affirming hormones or puberty blockers had significantly **lower odds of depression and suicidality** than those who did not receive treatment ([jamanetwork.com](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789423?previousarticle=0&widget=personalizedcontent#:~:text=After%20adjustment%20for%20temporal%20trends,CI%2C%200.41%2C%202.51)). The authors conclude that gender-affirming medical care was associated with improved short-term mental health and reduced self-harm/suicidal thoughts in youth. **(Link:** JAMA Netw Open, 5(2): e220978, open access via PMC **– PMID:** 35212746)**.

2. **Green et al., 2022** – *Large survey study (Journal of Adolescent Health) by The Trevor Project’s researchers.* Analyzed data from **over 9,000 trans and nonbinary youth** (ages 13–24). It reported that youth who *received* gender-affirming hormone therapy had markedly **lower rates of recent depression and suicide contemplation/attempts** than those who wanted treatment but couldn’t get it ([www.thetrevorproject.org](https://www.thetrevorproject.org/blog/new-study-finds-gender-affirming-hormone-therapy-linked-to-lower-rates-of-depression-suicide-risk-among-transgender-youth/#:~:text=,who%20supported%20their%20gender%20identity)) ([www.thetrevorproject.org](https://www.thetrevorproject.org/blog/new-study-finds-gender-affirming-hormone-therapy-linked-to-lower-rates-of-depression-suicide-risk-among-transgender-youth/#:~:text=was%20associated%20with%20nearly%2040,who%20received%20GAHT%20reporting%20they)). For trans youth under 18, getting hormone therapy was associated with about a **40% reduction in odds of depression and past-year suicide attempt** ([www.thetrevorproject.org](https://www.thetrevorproject.org/blog/new-study-finds-gender-affirming-hormone-therapy-linked-to-lower-rates-of-depression-suicide-risk-among-transgender-youth/#:~:text=,who%20supported%20their%20gender%20identity)). The authors interpret this as strong evidence that access to gender-affirming care is linked to better mental health and lower suicide risk in youth. **(Link: [PubMed](https://pubmed.ncbi.nlm.nih.gov/34920935/))**.

3. **Turban et al., 2020** – *Cross-sectional study (Pediatrics, AAP).* Examined U.S. transgender adults (ages 18–36) who retrospectively reported whether they received puberty-blocking treatment in adolescence. Among those who *wanted* puberty suppression, the individuals who actually received it had a **significantly lower lifetime risk of suicidal ideation** – an adjusted odds ratio of about 0.3 (70% lower odds) compared to those who wanted it but did not receive it ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7073269/#:~:text=assigned%20male%20sex%20at%20birth,confidence%20interval%20%3D%200.2%E2%80%930.6)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7073269/#:~:text=odds%20of%20lifetime%20suicidal%20ideation,confidence%20interval%20%3D%200.2%E2%80%930.6)). In other words, access to puberty blockers in youth was associated with far less suicidal thinking later on. The authors concluded that puberty suppression for transgender adolescents may confer mental health benefits and reduce suicidality. **(Link: [Pediatrics article](https://publications.aap.org/pediatrics/article/145/2/e20191725/76910/) or [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7073269/) – PMID: 31974216)**.

4. **de Vries et al., 2014** – *Long-term study from the Netherlands (Pediatrics).* Followed **55 transgender adolescents** who underwent a structured gender-affirming treatment protocol (puberty blockers in early teens, cross-sex hormones at ~16, and gender-affirming surgeries by 18). **Results:** After completing transition in young adulthood, participants’ **gender dysphoria was resolved and their psychological functioning dramatically improved** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25201798/#:~:text=Results%3A%20After%20gender%20reassignment%2C%20in,being)). Their subjective well-being (happiness, life satisfaction) was on par with or better than same-age peers **without** gender dysphoria ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25201798/#:~:text=Results%3A%20After%20gender%20reassignment%2C%20in,being)). Notably, none of these individuals regretted treatment, and the study reported high satisfaction with life – implying a positive impact on mental health and presumably a lower risk of suicidality post-treatment. This research supports the view that early gender-affirming intervention can lead to excellent mental health outcomes. **(Link: [Pediatrics 2014](https://pubmed.ncbi.nlm.nih.gov/25201798/))**.

5. **Jackson et al., 2023** – *Narrative review (Cureus journal).* Reviewed 23 studies on suicide-related outcomes after gender-affirming interventions (surgeries, hormones, puberty blockers). The **majority of studies indicated a reduction in suicidality** following gender-affirming care, according to the review ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10027312/#:~:text=is%20whether%20gender,enhancing%20and%20reducing)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10027312/#:~:text=inclusion%20criteria%2C%20the%20majority%20indicated,affirming)). However, the authors emphasize that **many studies had methodological limitations**, such as lack of control groups or short follow-up, which could inflate positive findings ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10027312/#:~:text=surgery%2C%20hormones%2C%20and%2For%20puberty%20blockers,be%20implications%20on%20the%20informed)). They call for more rigorous future research to confirm the extent that gender-affirming treatments causally reduce suicide risk. In summary, this review leans toward the view that gender-affirming care *does* seem to help reduce suicidality, but it urges caution and further study due to overall low quality of evidence in this area. **(Link: [Cureus 15(3):e36425](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027312/))**.

6. **Greene, 2022 (Heritage Foundation Report)** – *Contrary policy analysis.* This report by a Heritage Foundation researcher argued that *easing minors’ access* to puberty blockers and hormone therapies (for example, allowing treatment without parental consent) **did not lower youth suicide rates** at the population level; in fact, it asserted that such states **“likely” saw higher youth suicide rates** after adopting more permissive policies ([www.heritage.org](https://www.heritage.org/gender/report/puberty-blockers-cross-sex-hormones-and-youth-suicide#:~:text=Summary)) ([www.heritage.org](https://www.heritage.org/gender/report/puberty-blockers-cross-sex-hormones-and-youth-suicide#:~:text=medical%20interventions%20without%20parental%20consent,have%20primary%20responsibility%20for%20their)). The author’s view is that increasing use of medical transition in adolescents might be correlated with rising teen suicide rates, challenging the claim that gender-affirming care prevents suicides. **Critics note** that this analysis was not peer-reviewed and has methodological flaws (e.g. it uses broad state-level data over time without accounting for other variables). Nonetheless, it represents a skeptical viewpoint suggesting that gender-affirming interventions may not reduce suicide risk, contrary to most clinical studies. **(Link: [Heritage.org](https://www.heritage.org/gender/report/puberty-blockers-cross-sex-hormones-and-youth-suicide))**.